Patents Assigned to Kabi Pharmacia Aktiebolag
  • Preparation of fused proteins, antibodies and processes therefore
    Patent number: 5411732
    Abstract: A process for preparing antibodies specific for an amino acid sequence which comprises immunizing a mammal with a fused protein comprising said amino acid sequence fused to an immunogenic IgG binding protein is disclosed.
    Type: Grant
    Filed: October 1, 1993
    Date of Patent: May 2, 1995
    Assignee: Kabi Pharmacia Aktiebolag
    Inventors: Bjorn Lowenadler, Erik Holmgren, Mathias Uhlen, Bjorn Nilsson
  • Derivatives of quinoline-3-carboxanilide
    Patent number: 5310913
    Abstract: Compounds having formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are selected from the group consisting of hydrogen, hydroxy and methoxy. At most one of R.sup.1, R.sup.2 and R.sup.3 and at most one of R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is selected from the group consisting of hydroxy and methoxy. M is selected from the group consisting of hydrogen and pharmaceutically acceptable inorganic or organic cations or tautomeric forms thereof. The compounds have immunomodulating activity.
    Type: Grant
    Filed: August 5, 1993
    Date of Patent: May 10, 1994
    Assignee: Kabi Pharmacia Aktiebolag
    Inventors: Per O. Gunnarsson, Torbjorn Stalhandske, Kerstin Strandgarden, Karl-Erik Lundvall, Kaj Johansson
  • Emulsion for parenteral administration
    Patent number: 5244925
    Abstract: The invention relates to emulsions intended for parenteral administration and contaning a hydrophobic phase emulsified in a an aqueous phase. In accordance with the invention, a substantial part of the hydrophobic phase contains one or more alkyl esters of pharmacologically acceptable fatty acids, and particularly their ethyl esters. The emulsions can be used for parenteral nutrient supply and as vehicles for pharmacologically active substances or agents and may also be used for both purposes in combination.
    Type: Grant
    Filed: October 8, 1991
    Date of Patent: September 14, 1993
    Assignee: Kabi Pharmacia Aktiebolag
    Inventors: Karl A. J. Wretlind, Bengt M. Ajaxon
  • Compounds for the treatment of urinary incontinence
    Patent number: 5236956
    Abstract: The invention concerns compounds having the formula I ##STR1## wherein Ar is a phenyl or benzyl group which is optionally substituted with hydroxy or alkoxy;R.sup.1 is hydrogen, lower alkyl, lower alkoxy, hydroxy;R.sup.2 is hydrogen, lower alkyl;R.sup.3 is NR.sup.4 R.sup.5, whereinR.sup.4 and R.sup.5 which can be the same or different, are lower alkyl, or wherein R.sup.4 and R.sup.5, when taken together, form a ring with the nitrogen atom, whereby said ring optionally is substituted with lower alkyl;n is 0 or 1;m is 2 or 3 andtheir salts with physiologically acceptable acids and when the compounds can be in form of optical isomers, the racemic mixture and the individual isomers, for the treatment of disorders of the urinary bladder.
    Type: Grant
    Filed: October 7, 1991
    Date of Patent: August 17, 1993
    Assignee: Kabi Pharmacia Aktiebolag
    Inventors: Christer Sjogren, Rene Mollberg, Sten Kelfve
  • Substituted isoxazolidines and isoxazolines as intermediates for delimopinal
    Patent number: 5155220
    Abstract: The invention concerns intermediates having the formula ##STR1## wherein R is 2-propylpentyl optionally with one, two or three internal unsaturated bonds, or 2-substituted-2-propylpentyl optionally with one or two internal unsaturated bonds wherein the 2-substituent is a leaving group.
    Type: Grant
    Filed: February 19, 1991
    Date of Patent: October 13, 1992
    Assignee: Kabi Pharmacia Aktiebolag
    Inventors: Sven Hernestam, Bernt Thelin, Elisabeth Seifert, Arne Nilsson